title: [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
abstract: The incidence of prostate cancer is increasing and the patients are generally of relatively advanced age. There has been an increase in the use of hormonal therapy in such cases. However, hormonal therapy for prostate cancer increases the risk of fracture. Bisphosphonates have been reported to prevent the bone loss caused by hormonal therapy. Therefore, oral bisphosphonates will play an important role in preventing bone loss in prostate cancer patients undergoing hormonal therapy.
authors.affiliation: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science.
authors.forename: Kouji
authors.initials: K
authors.lastname: Izumi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000203:Activities of Daily Living; D000726:Androgen Antagonists / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007987:Gonadotropin-Releasing Hormone